Privitera G, Bezzio C, Figlioli G, D'Amico F, et al. Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis. Clin Gastroenterol Hepatol 2026 Jan 28:S1542-3565(26)00045.
PMID: 41616901